NASDAQ:CBST - Cubist Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cubist Pharmaceuticals logoCubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive CBST News and Ratings via Email

Sign-up to receive the latest news and ratings for CBST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:CBST
CUSIP22967810
Phone+1-781-8608660

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Cubist Pharmaceuticals (NASDAQ:CBST) Frequently Asked Questions

What is Cubist Pharmaceuticals' stock symbol?

Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) issued its earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to the consensus estimate of $305.50 million. The company's revenue was up 16.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.

Has Cubist Pharmaceuticals been receiving favorable news coverage?

Headlines about CBST stock have trended somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cubist Pharmaceuticals earned a media sentiment score of -0.20 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.91 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Cubist Pharmaceuticals?

Shares of CBST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Cubist Pharmaceuticals?

Cubist Pharmaceuticals' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.


MarketBeat Community Rating for Cubist Pharmaceuticals (CBST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe CBST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.